Status:

COMPLETED

Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subjects

Lead Sponsor:

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Conditions:

Depression

Eligibility:

All Genders

18-45 years

Phase:

PHASE1

Brief Summary

This study evaluates the safety, tolerability and pharmacokinetics of Ammoxetine Hydrochloride Enteric-coated Tablets in Chinese heathy subjects. Part of the participants will receive Ammoxetine Hydro...

Eligibility Criteria

Inclusion

  • Males and females age 18-45 years
  • Body weight ≥ 45kg (female) or 50Kg (male), 18 ≤ BMI ≤ 26
  • Vital signs, physical examinations and laboratory tests and other tests prove participants are healthy
  • Sign the informed consent form voluntarily and cooperate voluntarily to complete the test

Exclusion

  • Allergens (allergic to 2 or more drugs, food or pollen)
  • comorbid illness (mental illness, liver and kidney disease, gastrointestinal diseases, nervous system disease, or other systemic diseases)
  • have Clinically significant abnormal screening laboratory values.
  • Systolic pressure \> 140mmHg or diastolic \> 90 mmHg
  • Postural hypotension (systolic blood pressure drop by 20mmHg or diastolic blood pressure drop by 10mmHg after standing position)
  • The QTc period ≥ 450ms (male) or 470ms (female) or has a history of QTc extension
  • Smoking or alcohol consumption (14 units per week in the previous 4 weeks : 1 unit = beer 285mL, or 25mL of spirits, or 150 mL of wine; Daily smoking ≥ 5) or abusing in past year of drug and other substance
  • Have donated blood \> 400 ml within 8 weeks prior to screening
  • Participated in other clinical trials within 3 months prior to screening
  • Intaked too much caffeinated beverage or food within 4 weeks prior to screening. such as: Coffee, tea, chocolate, cola, red bull (no more than 6 units per day). 1 unit of caffeine = 1 cup of coffee (177.4 mL) = 2 pots of cola (354.9 mL) = 1 cup of tea (354.9 mL) = 1/2 cup energy drink = 85g chocolate
  • Have taken drugs that changed liver enzyme activity, such as dexamethasone, ketoconazole, rifampicin and omeprazole, were used within 4 weeks prior to screening
  • Have taken prescription drugs and OTC (except for the occasional use of acetaminophen and nasal sprays), herbs vitamins or minerals within 4 weeks prior to screening. The interval from prior treatment to screening should be at least 5 half-lives metablism which subjected to the longer half-life
  • Using any psychotropic drug or psychoactive substance
  • Women were screened for positive blood pregnancy
  • The subjects and their partners were not willing to take contraceptives during trial and six months after the study
  • Have a donor plan recently
  • Have participated in this trial
  • The researchers believe that anyone who is unfit to participate in this test will be involved

Key Trial Info

Start Date :

October 30 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 15 2019

Estimated Enrollment :

58 Patients enrolled

Trial Details

Trial ID

NCT03456388

Start Date

October 30 2017

End Date

February 15 2019

Last Update

February 20 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Sichuan huaxi hospital 1 ward.

Chengdu, Sichuan, China, 610000